

**Suicide risk and symptom reduction in patients assigned to placebo in
Duloxetine and Escitalopram clinical trials: analysis of the FDA summary
basis of approval reports**

Khan A, Schwartz K.

Annals of clinical psychiatry

2007; 19(1):31-36

ARTICLE IDENTIFIERS

DOI: 10.1080/10401230601163550

PMID: 17453659

PMCID: not available

JOURNAL IDENTIFIERS

LCCN: not available

pISSN: 1040-1237

eISSN: 1547-3325

OCLC ID: not available

CONS ID: not available

US National Library of Medicine ID: not available

This article was identified from a query of the SafetyLit database.